The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies

Abstract

Objectives

Based upon inflammatory-related factors in chronic systemic lupus erythematosus (SLE), as well as the long-term prescription of corticosteroids, metabolic syndrome (MetS) prevalence is expected to be higher in SLE patients than among those without SLE. The aim of this study was to systematically analyze: (1) the worldwide prevalence of MetS in patients with SLE using different criteria, (2) the risk of MetS in patients with SLE compared with those without SLE, and (3) the risk of MetS component in patients with SLE compared with healthy controls.

Methods

We searched international databases, such as: Web of Science, Medline, PubMed, Scopus, Embase, CABI, CINAHL, DOAJ and Google Scholar. The articles which reported the prevalence of MetS in SLE patients, between 2006 and 2017, were included in the study if they had a: clear study design, study time and location, sound sampling approach and appropriate statistical analyses. Studies without sufficient data to determine the prevalence of MetS were excluded. Also, studies in patients suffering from other clinical diseases were not included.

Results

The meta-analyses of the prevalence (40 studies (n = 6085)) and risk (20 studies (n = 2348)) of MetS in SLE patients were conducted separately. The pooled prevalence of MetS among SLE patients was found to be 26% (95% confidence interval (CI): 22–30%), but varied from 18% (95% CI: 11–25%) to 34% (95% CI: 25–42%), depending upon the diagnostic criteria used. The overall pooled odds ratio (OR) of MetS in SLE patients, compared with healthy controls, was (OR = 2.50; 95% CI: 1.86–3.35), but this ranged from (OR = 1.23; 95% CI: 0.61–2.49) to (OR = 10.71; 95% CI: 1.33–86.48), depending upon the criteria used. Also, the risk of high fasting blood sugar (FBS; OR = 1.59; 95% CI: 1.05–2.40), low high-density lipoprotein cholesterol (HDL-C; OR = 1.43; 95% CI: 1.02–2.01), high blood pressure (BP; OR = 2.76; 95% CI: 2.19–3.47), high triglycerides (TG; OR = 2.85; 95% CI: 2.05–3.95) and high waist circumference (WC; OR = 1.37; 95% CI: 0.97–1.94) were all found to be higher in SLE patients compared with healthy controls.

Conclusions

The risk of MetS was significantly higher in SLE patients, compared with healthy controls, even after adjusting for publication bias. Among MetS components, high TG and high BP were most strongly associated with SLE. Considering that high TG and high BP are preventable, there is an international need to implement effective interventions to reduce MetS components in SLE patients in order to prevent serious outcomes such as cardiovascular diseases and mortality.

Keywords

Global metabolic syndrome prevalence systemic lupus erythematosus meta-analysis

Get full access to this article

View all access options for this article.

References

Grundy

Cleeman

Daniels

et al.

Diagnosis and management of the metabolic syndrome. Circulation 2005; 112: 2735–2752.

Chung

Avalos

Oeser

et al.

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208–214.

Muniz

Pereira

Silva

Bonfá

Borba

. Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: beneficial effect of antimalarials. Arthritis Care Res 2015; 67: 1255–1262.

Negrón

Molina

Mayor

Rodríguez

Vilá

. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 2008; 17: 348–354.

Ward

. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338–346.

Urowitz

Bookman

Koehler

Gordon

Smythe

Ogryzlo

. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221–225.

Manzi

Meilahn

Rairie

et al.

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408–415.

Sabio

Zamora-Pasadas

Jiménez-Jáimez

et al.

Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008; 17: 849–859.

Svenungsson

Jensen-Urstad

Heimbürger

et al.

Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–1893.

10.

Bruce

Urowitz

Gladman

Ibañez

Steiner

. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor study. Arthritis Rheum 2003; 48: 3159–3167.

11.

Sinicato

Postal

de Oliveira

Rittner

Marini

Appenzeller

. Prevalence and features of metabolic syndrome in childhood-onset systemic lupus erythematosus. Clinical rheumatology 2017; 36: 1527.

12.

Das

Medeiros

De Oliveira

ÍMaX

Thaysa

Ribeiro

. Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age. Rheumatology international 2016; 36: 117.

13.

Hatef-Fard

Khodabandeh

Sahebari

Ghayour-Mobarhan

Rezaieyazdi

. Metabolic syndrome in lupus patients in northeast of Iran, and their lifestyle habits. Caspian J Internal Med 2016; 7: 195.

14.

Moher

Liberati

Tetzlaff

Altman

. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.

15.

Vandenbroucke

Von Elm

Altman

et al.

Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: e297.

16.

Modesti

Reboldi

Cappuccio

et al.

Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One 2016; 11: e0147601.

17.

Egger

Smith

Schneider

Minder

. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

18.

Grundy

Brewer

Cleeman

Smith

Lenfant

. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.

19.

Demir

Artim-Esen

Sahinkaya

et al.

Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus 2016; 25: 177–184.

20.

Parker

Urowitz

Gladman

et al.

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013; 72: 1308–1314.

21.

Parker

Urowitz

Gladman

et al.

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2015; 74: 1530–1536.

22.

Telles

Lanna

Ferreira

Ribeiro

. Metabolic syndrome in patients with systemic lupus erythematosus: Association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010; 19: 803–809.

23.

Liu

Han

Guo

et al.

Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. Lupus 2013; 22: 519–526.

24.

Hatef

Mirfeizi

Sahebari

Jokar

Mirheydari

. Superiority of laterally elevated wedged insoles to neutrally wedged insoles in medial knee osteoarthritis symptom relief. Int J Rheum Dis 2014; 17: 84–88.

25.

Akarsu

Ozbagcivan

Semiz

Aktan

. High prevalence of metabolic syndrome in patients with discoid lupus erythematosus: a cross-sectional, case-control study. J Immunol Res 2017. doi: 10.1155/2017/3972706.

26.

Ormseth

Swift

Fazio

et al.

Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus. Lupus 2013; 22: 26–33.

27.

Das Chagas Medeiros

de Oliveira

ÍMAX

Ribeiro

ÁTM

28.

Vadacca

Margiotta

Rigon

et al.

Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 2009; 36: 295–297.

29.

Hatef-Fard

Khodabandeh

Sahebari

Ghayour-Mobarhan

Rezaieyazdi

. Metabolic syndrome in lupus patients in northeast of Iran, and their lifestyle habits. Caspian J Internal Med 2016; 7: 195–200.

30.

Chung

Avalos

Oeser

et al.

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208–214.

31.

Parker

Ahmad

Shelmerdine

et al.

An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 2011; 20: 1459–1465.

32.

Margiotta

Navarini

Vadacca

et al.

Relationship between leptin and regulatory T cells in systemic lupus erythematosus: preliminary results. Eur Rev Med Pharmacol Sci 2016; 20: 636–641.

33.

Wang

Zheng

et al.

25-hydroxyvitamin D is associated with metabolic syndrome among premenopausal women with systemic lupus erythematosus in China. Lupus 2017; 26: 403–409.

34.

Sabio

Vargas-Hitos

Martinez-Bordonado

et al.

Association between low 25-hydroxyvitamin D, insulin resistance and arterial stiffness in nondiabetic women with systemic lupus erythematosus. Lupus 2015; 24: 155–163.

35.

Castejon

Jimenez-Ortiz

Rosado

Tutor-Ureta

Mellor-Pita

Yebra-Bango

. Metabolic syndrome is associated with decreased circulating endothelial progenitor cells and increased arterial stiffness in systemic lupus erythematosus. Lupus 2016; 25: 129–136.

36.

García-Villegas

Lerman-Garber

Flores-Suárez

Aguilar-Salinas

González

Villa-Romero

. Prognostic value of metabolic syndrome for the development of cardiovascular disease in a cohort of premenopausal women with systemic lupus erythematosus. Medicina Clínica (English Edition) 2015; 144: 289–296.

37.

Erdozain

Villar

Nieto

Ruiz-Irastorza

. Peripheral arterial disease in systemic lupus erythematosus: prevalence and risk factors. J Rheumatol 2014; 41: 310–317.

38.

Zhang

Cao

Qian

. Metabolic syndrome is correlated with carotid atherosclerosis in patients with lupus nephritis. Am J Med Sci 2014; 348: 486–491.

39.

Ugarte-Gil

Sánchez-Zúñiga

Gamboa-Cárdenas

et al.

Circulating naive and memory CD4 + T cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. Rheumatology 2014; 54: 1302–1307.

40.

Kawai

Avalos

Oeser

et al.

Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: Association with metabolic syndrome. Arthritis Care Res 2014; 66: 285–292.

41.

Valero-González

Castejon

Jimenez-Ortiz

et al.

Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. Scand J Rheumatol 2014; 43: 54–58.

42.

Gheita

Raafat

Sayed

El-Fishawy

Nasrallah

Abdel-Rasheed

. Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Zeitschrift Rheumatologie 2013; 72: 172–177.

43.

Santos

Pedro

Canhão

et al.

Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. Atherosclerosis 2011; 219: 821–826.

44.

Lozovoy

MAB

Simao

Hohmann

et al.

Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011; 20: 1356–1364.

45.

Mok

Poon

Lai

et al.

Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 2010; 39: 42–49.

46.

Sabio

Vargas-Hitos

Mediavilla

et al.

Correlation of asymptomatic hyperuricaemia and serum uric acid levels with arterial stiffness in women with systemic lupus erythematosus without clinically evident atherosclerotic cardiovascular disease. Lupus 2010; 19: 591–598.

47.

Bellomio

Spindler

Lucero

et al.

Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 2009; 18: 1019–1025.

48.

Zonana-Nacach

Santana-Sahagún

Jiménez-Balderas

Camargo-Coronel

. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008; 14: 74–77.

49.

Bultink

Turkstra

Diamant

Dijkmans

Voskuyl

. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26: 32.

50.

El Magadmi

Ahmad

Turkie

et al.

Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006; 33: 50–56.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.61 MB